348P First Findings from Synergy, a Phase I/Ii Trial Testing the Addition of the Anti-Cd73 Oleclumab (O) to the Anti-Pd-L1 Durvalumab (D) and Chemotherapy (Cht) as First Line Therapy for Patients (Pts) with Metastatic Triple-Negative Breast Cancer (Mtnbc)